{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-FB3UHPVU/25dd09ba-4c10-44e4-8c91-26f6ebdd0db4/HTML","dcterms:extent":"41 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-FB3UHPVU/a252db13-4576-4f71-aa0a-5d19c66cadee/PDF","dcterms:extent":"103 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-FB3UHPVU/c49a035f-ffef-4a00-8685-673fb6d421cf/TEXT","dcterms:extent":"38 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-FB3UHPVU","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2010","dc:creator":["Kos, Janko","Lah Turnšek, Tamara","Mirković, Bojana"],"dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:79"},{"@xml:lang":"sl","#text":"str. 146-155"}],"dc:identifier":["ISSN:1318-0347","COBISSID:2763633","URN:URN:NBN:SI:doc-FB3UHPVU"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"nanotehnologija"},{"@xml:lang":"sl","#text":"rak (medicina)"},{"@xml:lang":"en","#text":"therapy"},{"@xml:lang":"sl","#text":"zdravljenje"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Nanotehnologija pri zdravljenju raka| Nanotechnology in the treatment of cancer|"},"dc:description":[{"@xml:lang":"sl","#text":"Background: Chemotherapy can induce severe side eff ects in patients due to nonselective activity towards healthy cells during the treatment of cancer. This can lead to an alteration of the dosage regimen and in some cases to premature cancelation of chemotherapy, which reduces its therapeutic eff ect and prolongs the treatment period. Adverse side eff ects can also infl uence the patient's quality of life during and aft er the treatment. Inclusion of anti-tumour drugs in nanocarrier systems can reduce the adverse side eff ects by passive and/or active targeting of tumour cells. Conclusions: Nanocarrier systems achieve passive targeting of tumours through enhanced permeability and retention eff ect (EPR eff ect), which is mainly the result of leakiness of tumour vasculature. Furthermore, active targeting of tumour cells can be achieved through the conjugation of targeting ligands to the surface of nanoparticles, which selectively bind antigens or receptors overexpressed on the surface of tumour cells. In this way, the interaction between healthy tissue and anti-tumour drugs is reduced. Consequently, anti-tumour drugs formulated in nanocarriers have less side-eff ects and are safer in comparison with a free drug, thus enabling higher doses and better efficay of anti-tumour therapy. To date, European Medicines Agency (EMEA) and Food and Drug Administration (FDA) have approved nine nanocarrier-based medicines for the treatment of cancer. The safety of nanoparticles is yet to be fully explored. However, their toxicity is known to be enhanced with reactive oxygen species, which are associated with inflammation"},{"@xml:lang":"sl","#text":"Izhodišča: Zdravljenje rakavih bolezni s kemoterapijo ima zaradi neselektivnega delovanja citostatikov na deleče se zdrave celice številne neželene učinke. Zaradi pojava neželenih učinkov je včasih potrebno odmerek zdravila prilagoditi, ob hujših neželenih učinkih pa je zdravljenje potrebno celo prekiniti, kar proces zdravljenja podaljša in lahko vpliva na izid. Neželeni učinki kemoterapije poslabšajo tudi kakovost življenja bolnika med samim zdravljenjem in tudi po njem. Z vključevanjem protitumorskih učinkovin v nanodostavne sisteme (NS), ki pasivno in/ali aktivno ciljajo tumorske celice,se temu lahko izognemo. Zaključki: Vključevanje protitumorskih učinkovin v NS poveča zadrževanje učinkovine na mestu tumorja zaradi pasivnega ciljanja (učinka EPR), ki je posledica povečane prepustnosti tumorskega žilja. Še večjo selektivnost za tumorske celice dosežemo s pripenjanjem specifi čnih ligandov na površino NS, ki selektivno prepoznajo čezmerno izražene antigene ali receptorje na tumorskih celicah. Na ta način sezmanjša medsebojno delovanje protitumorskih učinkovin z zdravimi celicami. Formulacije protitumorskih učinkovin v NS imajo manj neželenih učinkov in so varnejše v primerjavi s prosto učinkovino, kar omogoča povišanje odmerka in tako izboljša učinkovitost zdravljenja. Do danes sta Evropska agencija za zdravila (EMEA) in Ameriška agencija za hrano in zdravila (FDA) za zdravljenjerakavih bolezni odobrili devet zdravil na osnovi NS. Kljub odobritvam pa varnost NS še ni zadosti raziskana. Toksičnost NS povezujejo z nastankom reaktivnih kisikovih presnovkov, k toksičnim učinkom NS pa naj bi pomembno prispevalo tudi medsebojno delovanje s celicami imunskega sistema in nezadostna specifičnost NS"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-FB3UHPVU","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-FB3UHPVU"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-FB3UHPVU/a252db13-4576-4f71-aa0a-5d19c66cadee/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-FB3UHPVU/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-FB3UHPVU"}}}}